DOCSLIB.ORG

(12) United States Patent (10) Patent No.: US 8,865,641 B2 Pavlov Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) United States Patent (10) Patent No.: US 8,865,641 B2 Pavlov Et Al USOO8865641B2 (12) United States Patent (10) Patent No.: US 8,865,641 B2 Pavlov et al. (45) Date of Patent: Oct. 21, 2014 (54) METHODS OF TREATMENT OF FATTY (2013.01); A61 K3I/46 (2013.01); A61 K LVER DISEASEBY PHARMACOLOGICAL 3 I/5513 (2013.01); A61K 31/167 (2013.01): ACTIVATION OF CHOLINERGIC PATHWAYS A6 IK3I/439 (2013.01) USPC ....... 514/1.1; 514/215: 514/220; 514/255.03; (75) Inventors: Valentin A. Pavlov, Bayside, NY (US); 514/278; 5.4394,51435,543 1 65 14/334: Kevin J. Tracey, Old Greenwich, CT 514471. 514/485; 514/614: 514/642 US) (58) Field of Classification Search ( None (73) Assignee: The Feinstein Institute for Medical See application file for complete search history. Research, Manhasset, NY (US) (56) References Cited (*) Notice: Subject to any disclaimer, the term of this U.S. PATENT DOCUMENTS patent is extended or adjusted under 35 U.S.C. 154(b) by 162 days. 6,610,713 B2 8/2003 Tracey 6,838,471 B2 1/2005 Tracey (21) Appl. No.: 13/523,519 7,238,715 B2 * 7/2007 Tracey et al. ................. 514,334 7,273,872 B2 9/2007 Tracey et al. 1-1. 7,662.965 B2 2/2010 Habgood et al. (22) Filed: Jun. 14, 2012 7,807,696 B2 10/2010 Al-Abed et al. O O 8,008.499 B2 8/2011 Habgood et al. (65) Prior Publication Data 2005/0125044 A1 6/2005 Tracey 2007/0173495 A1* 7, 2007 Palani et al. .................. 514,218 US 2012/0322719 A1 Dec. 20, 2012 2007/0213350 A1 9/2007 Tracey et al. 2009,0081314 A1 3, 2009 Wills 2011 OO15231 A1 1/2011 Al-Abed et al. Related U.S. ApplicationO O Data 2011/01661482011 0112128 A1 7/20115/2011 Tracey et al. (60) Provisional application No. 61/497,838, filed on Jun. 16, 2011. FOREIGN PATENT DOCUMENTS (51) Int. Cl. WO WO 2007OO1975 A1 : 1/2007 WO WO 2008/040548 A3 4/2008 A6 IK38/00 (2006.01) WO WO 2011006066 A1 * 1, 2011 AOIN 43/00 (2006.01) AOIN 43/46 (2006.01) OTHER PUBLICATIONS A6 IK3I/55 (2006.01) Guyenet S “Whole Helath Source: Choline and Fatty Liver” <http:// AOIN 43/62 (2006.01) wholehealthSource.blogspot.com/2010/11?choline-and-fatty-liver. A6 IK3I/4965 (2006.01) html> Accessed on the Internet Dec. 10, 2012. Published Nov. 29, AOIN 43/42 (2006.01) 2010.* A6 IK3I/44 (2006.01) Greenlee, W., et al., “Muscarinic agonists and antagonists in the AOIN 43/90 (2006.01) treatment of Alzheimer's disease.” Il Farmaco (56) pp: 247-250 AOIN 43/40 (2006.01) (2001). & 8 A6 IK3I/425 (2006.01) pay S.A. Slay liaisy's as AOIN 43/08 (2006.01) er, SV- state p Ca s 9-3 - A6 IK3I/34 (2006.01) Mice.” Mol Med 17(7-8):599-606 (Jul.-Aug. 2011). AOIN 47/10 (2006.01) * cited by examiner A6 IK3I/27 (2006.01) AOIN37/18 (2006.01) Primary Examiner — Maury Audet A6 IK3I/6 (2006.01) Assistant Examiner — Zachary J. Miknis AOIN33/12 (2006.01) (74) Attorney, Agent, or Firm — Hamilton, Brook, Smith & A6 IK3I/4 (2006.01) Reynolds, PC. A6 IK3I/444 (2006.01) A6 IK3I/495 (2006.01) (57) ABSTRACT A6 IK3I/34 (2006.01) A method of treating a fatty liver disease in a subject. The A6 IK3 L/4545 (2006.01) method comprises administering to the Subject an effective A6 IK3 L/46 (2006.01) amount of a cholinergic pathway stimulating agent, wherein A 6LX3/553 (2006.01) the fatty liver disease is selected from non-alcoholic fatty A6 IK3I/67 (2006.01) liver (NAFL), alcoholic fatty liver (AFL), non-alcoholic ste A6 IK3I/439 (2006.01) atohepatitis (NASH), alcoholic steatohepatitis (ASH), (52) U.S. Cl. NASH-associated liver fibrosis, ASH-associated liver fibro CPC ............... A6 IK3I/14 (2013.01); A61 K3I/444 sis, non-alcoholic cirrhosis, and alcoholic cirrhosis. (2013.01); A61 K3I/495 (2013.01); A61 K 3 I/55 (2013.01); A61 K3I/341 (2013.01); 29 Claims, 13 Drawing Sheets A6 IK3I/27 (2013.01); A61 K3I/4545 (2 of 13 Drawing Sheet(s) Filed in Color) U.S. Patent Oct. 21, 2014 Sheet 1 of 13 US 8,865,641 B2 FG. U.S. Patent Oct. 21, 2014 Sheet 2 of 13 US 8,865,641 B2 FG 2 U.S. Patent Oct. 21, 2014 Sheet 3 of 13 US 8,865,641 B2 (aamiasinouf) as euspoo : s 2 X { } {x : x is xi xi x) { {x x (f) fier Apog U.S. Patent US 8,865,641 B2 U.S. Patent Oct. 21, 2014 Sheet 6 of 13 US 8,865,641 B2 8 3. : 8 w : 3. X w r i & gx 3 & 8 : : « - - - - - - - - - - - - - - - . .----- - - - - - - - - - - 8;R &; : x 8 s: &s's & s: c U.S. Patent Oct. 21, 2014 Sheet 7 of 13 US 8,865,641 B2 c e (f) far dea xS xS. x S. : ex (if Yekaised U.S. Patent Oct. 21, 2014 Sheet 8 of 13 US 8,865,641 B2 i : U.S. Patent Oct. 21, 2014 Sheet 9 of 13 US 8,865,641 B2 U.S. Patent Oct. 21, 2014 Sheet 10 of 13 US 8,865,641 B2 ... c. it c it c is is Sun fielce) O Licenturiae pad ceded U.S. Patent Oct. 21, 2014 Sheet 11 of 13 US 8,865,641 B2 8 S. SSSSSSSSSSSSSS. SSkx: o: c grew r (fathasota is 8x8 pod K s: C e x-(6) ubiemK Apog U.S. Patent Oct. 21, 2014 Sheet 12 of 13 US 8,865,641 B2 s 3. 8: O eSEx. x. 388x Kei U.S. Patent Oct. 21, 2014 Sheet 13 of 13 US 8,865,641 B2 - 8: & i & ; : * & 8 : US 8,865,641 B2 1. 2 METHODS OF TREATMENT OF EATTY ergic pathway stimulating agent, wherein the fatty liver dis LIVER DISEASEBY PHARMACOLOGICAL ease is selected from non-alcoholic fatty liver (NAFL), alco ACTIVATION OF CHOLINERGC PATHWAYS holic fatty liver (AFL), non-alcoholic steatohepatitis (NASH), alcoholic steatohepatitis (ASH), NASH-associated RELATED APPLICATION liver fibrosis, ASH-associated liver fibrosis, non-alcoholic cirrhosis and alcoholic cirrhosis. This application claims the benefit of U.S. Provisional Application No. 61/497,838, filed on Jun. 16, 2011. BRIEF DESCRIPTION OF THE DRAWINGS The entire teachings of the above application are incorpo rated herein by reference. 10 The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application GOVERNMENT SUPPORT publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee. This invention was made with government Support under The foregoing will be apparent from the following more grant GM57226 awarded by the National Institutes of Health. 15 particular description of example embodiments of the inven The government has certain rights in the invention. tion, as illustrated in the accompanying drawings in which like reference characters refer to the same parts throughout BACKGROUND OF THE INVENTION the different views. The drawings are not necessarily to scale, emphasis instead being placed upon illustrating embodi Fatty liverdisease is a condition characterized by excessive ments of the present invention. accumulation of lipids (fat) in liver. The build-up offat in liver FIG. 1 is a table listing the components of a low-fat diet. results in a range of clinical manifestations and progresses in FIG. 2 is a table listing the components of a high-fat diet. stages. Depending on etiology, each stage can be character FIG. 3A is a plot showing the body weight of low-fat diet ized as non-alcoholic or alcoholic. The progression begins fed (control mice) and treated with saline (LFD-S), mice on a with simple fatty liver, or Steatosis. This stage, generally 25 high-fat diet and treated with saline (HFD-S) and mice on a regarded as benign, is characterized by the increased appear high-fat diet and treated with galantamine (HFD-G) as a ance of fat in the liver. Fatty liver can be characterized as function of time. non-alcoholic (NAFL) or alcoholic (AFL). The next stage of FIG. 3B is a bar graph showing the food intake of the a fatty liver disease is a form of hepatitis known as Steato groups of mice under study before and after treatment. hepatitis, characterized by further fat accumulation and liver 30 FIG. 4 shows Table 1, which provides data showing effect tissue inflammation. Steatohepatitis can be non-alcoholic of galantamine on abdominal adiposity. (NASH) or alcoholic (ASH). Both NASH and ASH can lead FIG. 5A through 5F are bar plots showing the measured to the next stage of fatty liver disease, NASH-associated or levels of the indicated analytes in the bloodstream of mice ASH-associated fibrosis, respectively, which is characterized under study. by Scarring of the liver. Finally, fibrosis can progress to cir 35 FIG. 6A through 6D are bar plots showing the measured rhosis, which causes irreversible damage to the liver and is the levels of the indicated analytes in the bloodstream of mice most severe stage. Cirrhosis can be non-alcoholic or alco under study. holic. FIG. 7A and FIG. 7B are bar plots showing plasma ALT Common risk factors for fatty liver disease are obesity, level and liver weight, respectively, in mice under study. diabetes and drinking alcohol to excess. While the relation 40 FIG. 8 is a photograph showing liver gross appearance in ship between these factors is not fully understood, they can be the three groups of mice.
Load more

Recommended publications
  • WITHOUTUS010307409B2 (12 ) United States Patent ( 10 ) Patent No
    WITHOUTUS010307409B2 (12 ) United States Patent ( 10 ) Patent No. : US 10 , 307 ,409 B2 Chase et al. (45 ) Date of Patent: Jun . 4 , 2019 ( 54 ) MUSCARINIC COMBINATIONS AND THEIR (52 ) U . S . CI. USE FOR COMBATING CPC . .. .. A61K 31/ 4439 (2013 . 01 ) ; A61K 9 /0056 HYPOCHOLINERGIC DISORDERS OF THE (2013 . 01 ) ; A61K 9 / 7023 ( 2013 . 01 ) ; A61K CENTRAL NERVOUS SYSTEM 31 / 166 ( 2013 . 01 ) ; A61K 31 / 216 ( 2013 . 01 ) ; A61K 31 /4178 ( 2013 .01 ) ; A61K 31/ 439 (71 ) Applicant: Chase Pharmaceuticals Corporation , ( 2013 .01 ) ; A61K 31 /44 (2013 . 01 ) ; A61K Washington , DC (US ) 31/ 454 (2013 .01 ) ; A61K 31/ 4725 ( 2013 .01 ) ; A61K 31 /517 (2013 .01 ) ; A61K 45 / 06 ( 72 ) Inventors : Thomas N . Chase , Washington , DC (2013 . 01 ) (US ) ; Kathleen E . Clarence -Smith , ( 58 ) Field of Classification Search Washington , DC (US ) CPC .. A61K 31/ 167 ; A61K 31/ 216 ; A61K 31/ 439 ; A61K 31 /454 ; A61K 31 /4439 ; A61K (73 ) Assignee : Chase Pharmaceuticals Corporation , 31 /4175 ; A61K 31 /4725 Washington , DC (US ) See application file for complete search history. ( * ) Notice : Subject to any disclaimer, the term of this (56 ) References Cited patent is extended or adjusted under 35 U . S . C . 154 (b ) by 0 days . U . S . PATENT DOCUMENTS 5 ,534 ,520 A 7 / 1996 Fisher et al. ( 21) Appl . No. : 15 /260 , 996 2008 /0306103 Al 12 /2008 Fisher et al. 2011/ 0021503 A1* 1/ 2011 Chase . .. A61K 31/ 27 ( 22 ) Filed : Sep . 9 , 2016 514 / 215 2011/ 0071135 A1 * 3 / 2011 Chase . .. .. .. A61K 31/ 166 (65 ) Prior Publication Data 514 / 215 2011 /0245294 Al 10 / 2011 Paborji et al.
    [Show full text]
  • Wo 2007/128674 A2
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date (10) International Publication Number 15 November 2007 (15.11.2007) PCT WO 2007/128674 A2 (51) International Patent Classification: Houtenlaan 36, NL-1381 CP Weesp (NL). KRUSE, Cor- A61K 31/00 (2006.01) A61K 31/551 (2006.01) nelis G. [NL/NL]; c/o SOLVAY PHARMACEUTICALS A61K 31/439 (2006.01) A61P 25/18 (2006.01) B.V., IPSI Department, CJ. Van Houtenlaan 36, NL-1381 A61K 31/4439 (2006.01) CP Weesp (NL). (21) International Application Number: (74) Agent: VERHAGE, Marinus; Octrooibureau Zoan B.V., PCT/EP2007/053934 NL-1380 AC Weesp (NL). (22) International Filing Date: 23 April 2007 (23.04.2007) (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, (25) Filing Language: English CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, (26) Publication Language: English IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY,MA, MD, MG, MK, MN, MW, MX, MY, (30) Priority Data: MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, 061 13476.3 4 May 2006 (04.05.2006) EP RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, 60/797,355 4 May 2006 (04.05.2006) US TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW (71) Applicant (for all designated States except US): SOLVAY (84) Designated States (unless otherwise indicated, for every PHARMACEUTICALS B.V.
    [Show full text]
  • (Tert- Butoxycarbonyl)Amino](3 361442- 3
    Alternative Name CAS 1. Product Name Use Number 320345- 2. Aclidinium bromide API 99-1 (2S)-[(tert- Butoxycarbonyl)amino](3 361442- 3. Saxagliptin int -hydroxyadamant-1- 00-4 yl)ethanoic acid 1,3- 1,3- 5001-18- 4. Dihydroxyadamantane Adamantanediol 3 1,3-Dimethyladamantane 702-79-4 memantine intermediate 5. 1-Acetylamido-3,5- 19982- 6. Memantine int dimethyladamantane 07-1 1- 7. 880-52-4 Acetylaminoadamantane 1- 4942-47- 8. 1-Adamantaneacetic acid Adamantylacetic 6 acid [2-(1- 6240-11- 9. 1-Adamantaneethanol Adamantylethano 5 l)] 1- 10. 1-Adamantanemethanol Adamantylmetha 770-71-8 nol 1- 1660-04- 1-Adamantyl methyl rimantadine intermediate; 11. Acetyladamantan 4 ketone e 1-Chloro-3,5- 707-36-8 memantine intermediate; 12. dimethyladamantane 1-Hydroxy-3,5- memantine intermediate; 13. 707-37-9 dimethyladamantane 2- 14. 2-Adamantanol Hydroxyadamant 700-57-2 ane 15. 2-Adamantanone 700-58-3 2-Aminoadamantane 10523- 16. hydrochloride 68-9 3-Amino-1-hydroxy- 3-Amino-1- 702-82-9 vildagliptin intermediate; 17. adamantane adamantanol 3- 38584- 18. (Hydroxymethyl)adamant 37-1 -1-ol 19. 3-aminomethyl- 865887- mequitazine intermediate; 20. quinuclidine 14-5 dihydrochloride zacopride intermediate; 6530-09- mezacopride intermediate; 3-Aminoquinuclidine 21. 2 pancopride intermediate; dihydrochloride azasetron intermediate; 3-Carbethoxy-dehydro- quifenadine intermediate; 50790- 22. quinuclidine sequifenadine intermediate; 85-7 hydrochloride quifenadine intermediate; 3- 6238-33- 23. sequifenadine intermediate; Carbethoxyquinuclidine 1 3-hydroxymethyl 79221- mequitazine intermediate; 24. quinuclidine 75-3 hydrochloride 3-Quinuclidine 6238-34- 25. carboxylic acid 2 hydrochloride 1619-34- penehyclidine intermediate; 26. 3-Quinuclidinol 7 clidinium intermediate; cevimeline intermediate; 3-Quinuclidinone 1193-65- 27.
    [Show full text]
  • Alzheimer's Disease Clinical Trials
    Clinical Trial Perspective 5 Clinical Trial Perspective Alzheimer’s disease clinical trials: past failures and future opportunities Clin. Invest. (Lond.) Over a decade has elapsed since the US FDA has approved a medication for Alzheimer’s Roy Yaari*,1,2 & Ann Hake1,2 disease (AD) despite clinical trials of numerous agents over a wide array of mechanisms 1Eli Lilly & Company, Lilly Corporate including neurotransmitter modulation and disease modifying therapy targeting Center, Indianapolis, IN 46285, USA 2Indiana University School of Medicine, amyloid and tau. The failures of clinical trials in AD may be due to inadequate Department of Neurology, Indianapolis, understanding of mechanisms of action and/or poor target engagement; however, IN 46202, USA other factors could include inadequate study design, stage of AD along the continuum *Author for correspondence: studied, inclusion of participants without Alzheimer’s pathology into clinical trials Tel.: +1 317 651 6163 and limited power of endpoint measures. Future studies will need to carefully assess [email protected] these possible shortcomings in design of upcoming trials, especially as the field moves toward studies of disease modifying agents (as opposed to symptomatic treatment) of AD and to patients that are very early in the disease spectrum. Keywords: Alzheimer’s disease • Alzheimer’s disease biomarkers • amyloid • clinical trials • preclinical Alzheimer’s disease • tau US FDA approved medications continue to provide significant, but modest More than three decades ago, the choliner- symptomatic benefit[5–7] . gic hypothesis proposed that degeneration The compound memantine introduced a of cholinergic neurons in the basal fore- second mechanism for symptomatic treat- brain and the associated loss of cholinergic ment of AD into clinical practice.
    [Show full text]
  • Structure-Based Discovery of Prescription Drugs That Interact with the Norepinephrine Transporter, NET
    Structure-based discovery of prescription drugs that interact with the norepinephrine transporter, NET Avner Schlessingera,b,c,1, Ethan Geiera, Hao Fana,b,c, John J. Irwinb,c, Brian K. Shoichetb,c, Kathleen M. Giacominia, and Andrej Salia,b,c,1 aDepartment of Bioengineering and Therapeutic Sciences, bDepartment of Pharmaceutical Chemistry, and cCalifornia Institute for Quantitative Biosciences, University of California, San Francisco, CA 94158 Edited by Barry Honig, Columbia University, Howard Hughes Medical Institute, New York, NY, and approved July 20, 2011 (received for review April 15, 2011) The norepinephrine transporter (NET) transports norepinephrine transporter (SERT, SLC6A4) (4). Because of the lack of high- from the synapse into presynaptic neurons, where norepinephrine resolution structural information, most drug discovery efforts regulates signaling pathways associated with cardiovascular targeting NET and other SLC6 transporters, including SERT and effects and behavioral traits via binding to various receptors dopamine transporter (DAT,SLC6A3), have relied on quantitative (e.g., β2-adrenergic receptor). NET is a known target for a variety structure-activity relationship (QSAR) approaches and pharmaco- of prescription drugs, including antidepressants and psychosti- phore modeling (5). mulants, and may mediate off-target effects of other prescription As for other SLC6 family members, NET is predicted to have drugs. Here, we identify prescription drugs that bind NET, using one domain containing 12 transmembrane helices (2). No struc- virtual ligand screening followed by experimental validation of tures of human SLC6 members have been determined at atomic predicted ligands. We began by constructing a comparative struc- resolution; however, the leucine transporter LeuT from the bac- tural model of NET based on its alignment to the atomic structure terium Aquifex aeolicus has been determined by X-ray crystallo- of a prokaryotic NET homolog, the leucine transporter LeuT.
    [Show full text]
  • 30Th Annual Meeting of Society for Neuroscience. New Drugs Affecting the Central Nervous System New Orleans, Louisiana, USA November 4–9, 2000
    CNS Drug Reviews Vol. 7, No. 2, pp. 241–248 © 2001 Neva Press, Branford, Connecticut MEETING REPORT 30th Annual Meeting of Society for Neuroscience. New Drugs Affecting the Central Nervous System New Orleans, Louisiana, USA November 4–9, 2000 Alexander Scriabine Yale University School of Medicine, New Haven, CT, USA The 30th meeting of the Society for Neuroscience was held on November 4–9 in New Orleans, LA, USA. The meeting was attended by ~25,000 scientists and exhibitors. There were 874 slide or poster sessions, symposia or special lectures. Each session contained 10 to 20 presentations. This report covers only selected posters on new drugs affecting the central nervous system. NEUROPROTECTIVE DRUGS M. Cheng et al. (Centaur Pharmaceuticals, Inc., Sunnyvale, CA, USA) presented NXY-50, a novel free radical trapping agent, that was found to reduce infarct volume in rats with permanent focal ischemia induced by occlusion of middle cerebral artery (MCAO). The drug (30 or 60 mg/kg) was administered at 5 min after MCAO by i.v. bolus followed by infusion for 24 h (same dose per hour). The animals were sacrificed at 24 h after MCAO. The infarct volumes were estimated by histochemical staining. At 60 mg/kg the effect of the drug was statistically significant. J. Peeling et al. (Univ. of Mannitoba, Winnipeg, Canada, Memorial Univ., St. John’s, Newfoundland, Canada and AstraZeneca, Loughborough, UK and Södertalje, Sweden) studied NXY-059 in a rat model of hemorrhagic stroke. Intracerebral hemorrhage (ICH) was induced in rats by infusion of collagenase into SO Na 3 the right caudate nucleus.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2007/0099986 A1 Ishiichi Et Al
    US 2007.0099986A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2007/0099986 A1 Ishiichi et al. (43) Pub. Date: May 3, 2007 (54) PREVENTIVES/REMEDIES FOR URINARY (57) ABSTRACT DISTURBANCE A compound represented by the formula: (76) Inventors: Yuji Ishichi, Osaka (JP): Koichi (I) Iwanaga, Osaka (JP); Tomomi H Ikemoto, Osaka (JP); Hiroaki Ar-X-L-N-CHCH Yamamoto, Osaka (JP); Shokyo Miki, Osaka (JP) CFO Correspondence Address: WENDEROTH, LIND & PONACK, L.L.P. wherein Ar represents a group represented by the formula: 2O33 K STREET N. W. w w SUTE 8OO t w WASHINGTON, DC 20006-1021 (US) w ,w RNHSO, w t O (21) Appl. No.: 11/589,903 Y RO RI (22) Filed: Oct. 31, 2006 (30) Foreign Application Priority Data C x, O Nov. 2, 2005 (JP)...................................... 2005-319789 SONHR Publication Classification (wherein Y represents methylene or an oxygen atom, R' (51) Int. Cl. represents aminosulfonyl, C. alkylaminosulfonyl, C. A6 IK 3/343 (2006.01) alkylcarbonylamino or C. alkylsulfonylamino, R repre A6 IK 3/36 (2006.01) sents a hydrogen atom or C. alkyl, R represents C-alkyl, CO7D 39/4 (2006.01) and R' represents a hydrogen atom or C- alkyl); X repre A6 IK 3/8 (2006.01) sents a carbonyl group, or a methylene group which may be CD7C 3II/8 (2006.01) Substituted with a hydroxy group; and L represents an (52) U.S. Cl. ......................... 514/452: 514/469: 514/602; optionally substituted Cas alkylene group, or a salt thereof 564/86; 549/467; 549/362 is provided.
    [Show full text]
  • Alzheimer Syllabus
    Update on Alzheimer’s Disease June, 2006 Stephen S. Flitman, MD, Medical Director 21 st Century Neurology 3100 North Third Ave Suite 100, Phoenix, Arizona (602) 265-6500 www.neurozone.org Alzheimer’s Disease (AD), first described by Dr. Alois Alzheimer in 1907, is a disorder that 10 million Americans are thought to have, but less than 40% are diagnosed or receiving treatment now. It is very common, affecting people ages 40-90 with 2-4% prevalence at ages 65- 75 and increasing in subsequent decades. After heart disease, cancer, and stroke it is the fourth leading cause of death in the US. AD is a disorder of the gray matter of the cerebral cortex. It is characterized clinically by gradually progressive dementia and pathologically by extraneuronal plaques and intraneuronal neurofibrillary tangles by light microscopy. AD progresses anatomically via the connections made by affected neurons. It starts in the entorhinal cortex and then spreads to the hippocampus, basal nuclei, and then to the neocortex. It spares primary motor and sensory cortices, preferentially attacking association areas in the frontal, parietal, and temporal lobes. Affected regions have neurochemical deficits of acetylcholine, glutamate, and serotonin. The degree of dementia correlates with the decline in these neurotransmitters in biopsy or autopsy tissue. While short-term memory deficits predominate early in the progressive dementias, the term dementia is reserved for a clinical syndrome of memory disorder plus at least one other cognitive realm: language, motor or procedural memory (praxis), spatial function, and executive function (decision-making, planning, overall control of behavior). As an etiology for dementia, AD accounts for about two-thirds of cases, with metabolic causes and Lewy body disease making up the lion’s share of the remaining third.
    [Show full text]
  • The Action of Xanomeline on Human Muscarinic Receptors Expressed in Chinese Hamster Ovary Cells
    The action of xanomeline on human muscarinic receptors expressed in Chinese hamster ovary cells A DISSERTATION SUBMITTED TO THE FACULTY OF THE GRADUATE SCHOOL OF THE UNIVERSITY OF MINNESOTA BY MEREDITH NOETZEL IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF DOCTOR OF PHILOSOPHY Advisor: Dr. Esam El-Fakahany JANUARY, 2009 © Meredith Noetzel, January 2009 Acknowledgements I would like to thank my advisor Dr. Esam El-Fakahany for his support and guidance. He kindly let me join his lab and be his last graduate student. He has also helped me to grow as a scientist. I would like to thank my committee members Dr. Virginia Seybold, Dr. William Engeland and Dr. Ping Law for their time and advice. Without their thoughtful input I would not have been able to complete my thesis as quickly. They have also been instrumental in helping me learn to present my work in a clear and concise manner. The El-Fakahany lab members that I have worked with have been great. I would especially like to thank Marianne Grant for all of her help and support. She was always there to teach me new techniques, answer questions and help with anything. Without her I would not have been able to get everything done. I would also like to thank Kayla De Lorme and Allison Cherry for the great conversions and making the lab a fun place to be. I would also like to acknowledge both Marianne Grant and Kayla De Lorme for providing some of the data presented in this thesis. I would also like to thank my former lab.
    [Show full text]
  • United States Patent (10) Patent No.: US 8,003,632 B2 Tracey Et Al
    US008.003632B2 (12) United States Patent (10) Patent No.: US 8,003,632 B2 Tracey et al. (45) Date of Patent: Aug. 23, 2011 (54) CHOLINESTERASE INHIBITORS FOR Sg: A t 3. Ryaninomiya et et alal. TREATING INFLAMMATION 5,536,728 A 7/1996 Ninomiya et al. 5,554,780 A 9, 1996 Wolf (75) Inventors: Kevin J. Tracey, Old Greenwich, CT 5,693,668 A 12, 1997 Sain et al. (US); Valentin A. Pavlov, Ridgewood, 5,760,267 A 6/1998 Gandolfi et al. NY (US) 5,861.411 A 1/1999 Ninomiya et al. 5,929,084 A 7, 1999 Zhu et al. 5,981,549 A 11, 1999 V (73) Assignee: The Feinstein Institute for Medical 6, 194403 B1 2, 2001 E. al. Research, Manhasset, NY (US) 6,433,173 B1 8, 2002 Omori 6,610,713 B2 * 8/2003 Tracey .......................... 514,343 (*) Notice: Subject to any disclaimer, the term of this 6,838,471 B2 ck 1/2005 Tracey ded or adiusted under 35 2003. O139391 A1 7/2003 Parys et al. .............. 514,214.03 patent 1s extende 2004/0214.863 A1 10, 2004 Pratt U.S.C. 154(b) by 0 days. FOREIGN PATENT DOCUMENTS (21) Appl. No.: 11/893,116 EP O 633 251 A1 1/1995 JP 571 14512 7, 1982 (22) Filed: Aug. 14, 2007 WO WO98/OO119 A 1, 1998 9 WO WO99,08672 2, 1999 O O WO WOO1,89526 A 11, 2001 (65) Prior Publication Data WO WO 2004/034963 A 4, 2004 US 2008/OO70901 A1 Mar. 20, 2008 OTHER PUBLICATIONS Rees et al., Cardiovascular Research (1993)27:453-458.* Related U.S.
    [Show full text]
  • Drugs Used in Alzheimer Disease
    Drugs used in Alzheimer disease The causes and symptoms of Alzheimer’s disease (AD) According to the definition of the International Classification of Diseases (ICD-10), dementia - a complex of symptoms of pluricausal etiology. It is caused by brain disease and is usually chronic and progressive. In AD such higher cortical functions as memory, thinking, understanding, ability to learn and speak, perception of time and space as well as the ability to care for oneself are impaired. 1 Drugs used in Alzheimer disease The damage of cognitive functions is accompanied by diminished emotional control, dysfunctional social behaviour and decreased motivation. Consciousness is not affected in dementia states. An increased number of dementia states and depression syndromes are observed in people above the age of 65. The number of dementia cases increases in geometric progression and doubles every 5 years. About 350 000 people suffer from Alzheimer’s disease in Poland and about 25 mln worldwide. 2 Drugs used in Alzheimer disease A person’s age and a history of dementia in his or her family are considered to be hazard factors related to Alzheimer’s disease. Women are observed to be affected by Alzheimer’s disease more often than men. However this is not a result of sex differences but a reflection of the fact that women live longer. Less educated people seem to be affected more often and more severely. Between 10% and 15% of cases of AD are of genetic origin. 3 Drugs used in Alzheimer disease At present the following classification of AD cases is used: early-onset Alzheimer’s disease (affecting individuals aged below 60-65) late-onset Alzheimer’s disease.
    [Show full text]
  • Lessons Learned
    Prevention and Reversal of Chronic Disease Copyright © 2019 RN Kostoff PREVENTION AND REVERSAL OF CHRONIC DISEASE: LESSONS LEARNED By Ronald N. Kostoff, Ph.D., School of Public Policy, Georgia Institute of Technology 13500 Tallyrand Way, Gainesville, VA, 20155 [email protected] KEYWORDS Chronic disease prevention; chronic disease reversal; chronic kidney disease; Alzheimer’s Disease; peripheral neuropathy; peripheral arterial disease; contributing factors; treatments; biomarkers; literature-based discovery; text mining ABSTRACT For a decade, our research group has been developing protocols to prevent and reverse chronic diseases. The present monograph outlines the lessons we have learned from both conducting the studies and identifying common patterns in the results. The main product of our studies is a five-step treatment protocol to reverse any chronic disease, based on the following systemic medical principle: at the present time, removal of cause is a necessary, but not necessarily sufficient, condition for restorative treatment to be effective. Implementation of the five-step treatment protocol is as follows: FIVE-STEP TREATMENT PROTOCOL TO REVERSE ANY CHRONIC DISEASE Step 1: Obtain a detailed medical and habit/exposure history from the patient. Step 2: Administer written and clinical performance and behavioral tests to assess the severity of symptoms and performance measures. Step 3: Administer laboratory tests (blood, urine, imaging, etc) Step 4: Eliminate ongoing contributing factors to the chronic disease Step 5: Implement treatments for the chronic disease This individually-tailored chronic disease treatment protocol can be implemented with the data available in the biomedical literature now. It is general and applicable to any chronic disease that has an associated substantial research literature (with the possible exceptions of individuals with strong genetic predispositions to the disease in question or who have suffered irreversible damage from the disease).
    [Show full text]